Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 500 shares, a decrease of 92.2% from the March 31st total of 6,400 shares. Based on an average daily volume of 340,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Provectus Biopharmaceuticals Stock Down 0.9 %

OTCMKTS PVCT opened at $0.10 on Monday. Provectus Biopharmaceuticals has a 52 week low of $0.04 and a 52 week high of $0.20. The stock’s 50-day moving average price is $0.10 and its 200-day moving average price is $0.11.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.